Hydrix (ASX:HYD) said that Gyder Surgical, a client and investee, has received US Food and Drug Administration (FDA) clearance to sell its Gyder Hip System in the United States, according to a Monday filing with the Australian bourse.
The system, which is a pin-less and image-less navigation solution for hip surgery, has also been approved by Australia's Therapeutic Goods Administration, the filing said.
The FDA approval triggers an AU$0.3 million equity payment to Hydrix Ventures, increasing its investment in Gyder to AU$2.65 million, the filing added.
Shares of the company rose 67% at market close, and earlier hit a 52-week high.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。